Late-onset ankylosing spondylitis and spondylarthritis: An update on clinical manifestations, differential diagnosis and pharmacological therapies

Drugs and Aging

Volumn 27, Issue 7, 2010, Pages 523-531

  Toussirot, Éric ^a,b,c  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c HÔPITAL SAINT JACQUES   (France)

Author keywords

adalimumab, therapeutic use; ankylosing spondylitis; elderly; etanercept, therapeutic use; infliximab, therapeutic use; nonsteroidal anti inflammatories, therapeutic use; spondylarthritis, tumour necrosis factor alpha inhibitors, therapeutic use.

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; HLA B27 ANTIGEN; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; ARTHRITIS; BACKACHE; BONE MARROW EDEMA; COMORBIDITY; CROHN DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENTHESITIS; INCIDENCE; INFECTION; LEG; MYELITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSSIFICATION; OSTEITIS; OSTEOARTHRITIS; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; REVIEW; SACROILIAC JOINT; SACROILIITIS; SPINE MOBILITY; SPONDYLARTHRITIS; ULCERATIVE COLITIS; UVEITIS; VISUAL ANALOG SCALE; AGE; DRUG ANTAGONISM; HOSPITALIZATION; HUMAN; MALE; ONSET AGE; PATHOPHYSIOLOGY; SEX DIFFERENCE;

AGE FACTORS; AGE OF ONSET; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; MALE; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SPONDYLARTHRITIS; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954162456     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11315970-000000000-00000     Document Type: Review

References (53)

1. Calin A. Terminology, introduction, diagnostic criteria and overview. In: Calin A, Taurog JD, editors. The spondylarthritides. Oxford UK: Oxford University Press, 1998: 1-15
2. Toussirot E, Wendling D. Current guidelines for the drug treatment of ankylosing spondylitis. Drugs 1998; 56: 225-240
3. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of seronegative spondylarthropathies. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1999; 42: 2325-2329
4. Gonzalez-Lopez L, Garcia-Gonzalez A, Vasquez-Del- Mercado M, et al. Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. J Rheumatol 2004; 31: 1568-1574
5. Wendling D, Toussirot E. Anti-TNFa therapy in ankylosing spondylitis. Exp Opin Pharmacother 2004; 5: 1497-1507
6. Toussirot E, Wendling D. Late onset ankylosing spondylitis and related spondylarthropathies: clinical and radiological characteristics and pharmacological treatment options. Drugs Aging 2005; 22: 451-469
7. Carbone LD, Cooper C, Michet CJ, et al. Ankylosing spondylitis in Rochester, Minnesota 1935-1989. Is the epidemiology changing? Arthritis Rheum 1992; 35: 1476-1482
8. Rudwaleit M, Van der Heijde DM, Landewé R, et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. AnnRheum Dis 2009; 69: 777-783
9. Rudwaleit M, Jurik AG, Hermann KG, et al. Defining active sacroiliitis on magnetic resonance imaging for classification of axial spondylarthritis: a consensual approach by ASAS/OMERACT MRI group. Ann Rheum Dis 2009; 68: 1520-1527
10. Weber U, Hodler J, Kubik RA et al. Sensitivity and specificity of spinal inflammatory lesions assessed by whole body magnetic resonance imaging in patients with ankylosing spondylitis or recent onset inflammatory back pain. Arthritis Rheum 2009; 61: 900-908
11. Dubost JJ, Sauvezie B. Late onset peripheral spondylarthropathy. J Rheumatol 1989; 16: 1214-1217
12. Caplanne D, Tubach F, Le Parc JM. Late onset spondylarthropathy: clinical and biological comparison with early onset patients. Ann Rheum Dis 1997; 56: 176-179
13. Olivieri I, Padula A, Pierro A, et al. Late onset seronegative spondylarthropathy. J Rheumatol 1995; 22: 899-903
14. Punzi L, Pianon M, Rossini P, et al. Clinical and laboratory manifestations of elderly onset psoriatic arthritis: a comparison with younger onset disease. Ann Rheum Dis 1999; 58: 226-229
15. Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda- Filloy JA, et al. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine 2009; 88: 358-365
16. Peters MJ, Visman I, Nielsen MM, et al. Ankylosing spondylitis; a risk factor for myocardial infarction? Ann Rheum Dis 2010; 69: 579-581
17. Gilworth G, Emery P, Barkham N, et al. Reducing work disability in ankylosing spondylitis: development of a work instability scale for AS [abstract]. BMC Musculoskelet Disord 2009; 10: 68
18. Montacer KchirM,Mehdi GhannouchiM, Hamdi W, et al. Impact of the ankylosing spondylitis on the professional activity. Joint Bone Spine 2009; 76: 378-382
19. Singh JA, Strand V. Spondylarthritis is associated with poor function and physical health related quality of life. J Rheumatol 2009; 36: 1012-1020
20. Kujath K, Hermann KG, Mathiske-Schmidt K, et al. Severe disease activity and complications of immunosuppressive therapy: a challenge for acute hospital based rehabilitation in rheumatology. J Rheumatol 2009; 36: 1618-1625
21. Healey EL, Haywood KL, Jordan KP, et al. Ankylosing spondylitis and its impact on sexual relationships. Rheumatology 2009; 48: 1378-1381
22. Martindale J, Smith J, Sutton CJ, et al. Disease and psychological status in ankylosing spondylitis. Rheumatology 2006; 45: 1288-1293
23. McCarty DJ, O'Duffy JD, Pearson L, et al. Remitting synovitis seronegative symmetric synovitis with pitting edema (RS3PE) syndrome. JAMA 1985; 254: 2763-2767
24. Olivieri I, Pipitone N, D'Angelo S, et al. Late onset rheumatoid arthritis and late onset spondylarthritis. Clin Exp Rheumatol 2009; 27 Suppl. 55: S139-45
25. Olivieri I, D'Angelo S, Palazzi C, et al. Diffuse idiopathic skeletal hyperostosis: differentiation from ankylosing spondylitis. Curr Rheumatol Rep 2009; 11: 321-328
26. Lukas C, Landewé R, Sieper J, et al., Assessment of SpondyloArthritis international Society. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68: 18-24
27. Anderson JJ, Baron G, Van Der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44: 1876-1886
28. Inman RD, Davis JC, Van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008; 58: 3402-3412
29. Melmed GY, Targan SR, Yasothan U, et al. Certolizumab pegol. Nat Rev Drug Discov 2008 Aug; 7 (8): 641-642
30. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 2002; 359: 1187-1193
31. Davis JC, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48: 3230-3236
32. Van der Heijde D, Kivitz A, Schiff M, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 2136-2146
33. Van der Heijde D, Landewé R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008; 58: 3063-3070
34. Braun J, Baraliakos X, Listing J, et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005; 52: 2447-2451
35. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-390
36. Antoni C, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2005; 52: 1227-1236
37. Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Arthritis Rheum 2007; 56: 476-488
38. Braun J, Davis J, Dougados M, et al. First update of the international consensus statement for the use of anti TNFa agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65: 316-320
39. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68: 1387-1394
40. Radovits BJ, Kievit W, Laan RFJM. Tumour necrosis factor a antagonists in the management of rheumatoid arthritis in the elderly: a review of their efficacy and safety. Drugs Aging 2009; 26: 647-664
41. Fleischmann R, Baumgartner SW, Weisman MH, et al. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis 2006; 65: 379-384 (Pubitemid 43268229)
42. Fleischmann R, Iqbal I. Risk : benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. Drugs Aging 2007; 24: 239-254
43. Schneeweiss S, Setoguchi S, Weinblatt L, et al. Anti-tumor necrosis factor a therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 1754-1764
44. Genevay S, Finchk A, Ciurea A, et al. Tolerance and effectiveness of anti-tumor necrosis factor a therapies in elderly patients with rheumatoid arthritis: a population based cohort study. Arthritis Rheum 2007; 57: 679-685
45. Radovits BJ, Kievit W, Fransen J, et al. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1470-1473
46. Bathon JM, Fleischmann R, Van der Heijde DM, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol 2006; 33: 234-243 (Pubitemid 43209297)
47. Fillipini M, Bazzani C, Favalli EG, et al. Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. Clin Rev Allerg Immunol. Epub 2009 Jun 23
48. Ornetti P, Chevillotte H, Zerrak A, et al. Anti-tumour necrosis factor a therapy for rheumatoid arthritis and other inflammatory arthropathies: update on safety in older patients. Drugs Aging 2006; 23: 855-860
49. Tran S, Hooker RS, Cipher DJ, et al. Patterns of biologic agent use in older males with inflammatory diseases: an institution-focused, observational post marketing study. Drugs Aging 2009; 26: 607-615
50. Migliore A, Bizzi E, Lagana B, et al. The safety of anti TNFa agents in the elderly. Int J Immunopathol Pharmacol 2009; 22: 415-426
51. Chevillotte-Maillard H, Ornetti P, Mistrih R, et al. Survival and safety of treatment with infliximab in the elderly population. Rheumatology 2005; 44: 695-696
52. Setoguchi S, Schneeweiss S, Avorn J, et al. Tumor necrosis factor a antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am J Heart 2008; 156: 336-341
53. Diaz-Borjon A. Guidelines for the use of conventional and newer disease modifying antirheumatic drugs in elderly patients with rheumatoid arthritis. Drugs Aging 2009; 26: 273-293